This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognizing you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful. Check our privacy policy here.
Pipeline
OST-122 (IBD, fibrosis, CRC)
Oral, non-systemic JAK3/TYK2-ARK5 inhibitor
OST-499 (Uterine Fibroids)
Oral, non-steroidal PR antagonist
OST-664 (Fibrosis)
Oral ARK5 inhibitor
OST-122
Our lead program is a safer, non-systemic JAK inhibitor, OST-122, which is being developed as a local treatment for IBD (inflammatory bowel disease). Orally administered, OST-122 acts exclusively in the gastrointestinal tract, avoiding the severe systemic toxicities associated with other JAK inhibitors.
In a Phase 2a proof-of-concept clinical trial in patients with moderate to severe ulcerative colitis, GI-restricted OST-122 was well tolerated during the 4-week treatment period. Its excellent safety profile, minimal systemic absorption and promising clinical activity may provide a safer therapeutic option for a broad range of UC patients.
The program is open for licensing.
OST-499
Our second clinical program is focused on the development of OST-499, a non-steroidal progesterone receptor antagonist, for the treatment of uterine fibroids and other gynecological disorders.